TOBRAMYCIN SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C18H37N5O9.5H2O4S
Molecular Weight	1425.421
Optical Activity	UNSPECIFIED
Defined Stereocenters	28 / 28
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O.NC[C@H]4O[C@H](O[C@@H]5[C@@H](N)C[C@@H](N)[C@H](O[C@H]6O[C@H](CO)[C@@H](O)[C@H](N)[C@H]6O)[C@H]5O)[C@H](N)C[C@@H]4O

InChI

InChIKey=NZKFUBQRAWPZJP-BXKLGIMVSA-N

InChI=1S/2C18H37N5O9.5H2O4S/c2*19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18;5*1-5(2,3)4/h2*5-18,24-28H,1-4,19-23H2;5*(H2,1,2,3,4)/t2*5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+;;;;;/m00...../s1

HIDE SMILES / InChI

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C18H37N5O9
Molecular Weight	467.5145
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	14 / 14
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205433s000lbl.pdf
Curator's Comment: Description was created based on several resourses, including http://www.drugbank.ca/drugs/DB00684

Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
30S ribosomal protein S12 20 Target ID: CHEMBL1641336 Sources: http://www.drugbank.ca/drugs/DB00684#targets	Inhibitor 8504		9.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
External infections of the eye 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50541slr017_tobrex_lbl.pdf	Curative		Approved 8583	TOBREX Approved Use external infections of the eye Launch Date 1980
Cystic fibrosis 120 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205433s000lbl.pdf	Primary		Approved 8583	KITABIS PAK Approved Use cystic fibrosis Launch Date 2014

C_max

Value	Dose	Co-administered	Analyte	Population
3.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
814 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN sputum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
11.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN sputum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN sputum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6440126	unhealthy, 2 months - 27 years Health Status: unhealthy Age Group: 2 months - 27 years Sources: https://pubmed.ncbi.nlm.nih.gov/6440126	Sources: https://pubmed.ncbi.nlm.nih.gov/6440126
300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	Other AEs: Forced expiratory volume decreased, Rales... Other AEs: Forced expiratory volume decreased (31%) Rales (19%) Red blood cell sedimentation rate increased (8%) Dysphonia (6%) Wheezing (5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	Other AEs: Hypersensitivity, Eyelids itchy sensation of... Other AEs: Hypersensitivity Eyelids itchy sensation of Swelling Redness of eyelid conjunctiva Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
1.5 mg/kg 3 times / day multiple, intramuscular Dose: 1.5 mg/kg, 3 times / day Route: intramuscular Route: multiple Dose: 1.5 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/820195	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/820195	Sources: https://pubmed.ncbi.nlm.nih.gov/820195
2 mg/kg single, intraperitoneal Dose: 2 mg/kg Route: intraperitoneal Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/3950451	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/3950451	Sources: https://pubmed.ncbi.nlm.nih.gov/3950451

AEs

AE	Significance	Dose	Population
Rales	19%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Forced expiratory volume decreased	31%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Wheezing	5%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Dysphonia	6%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Red blood cell sedimentation rate increased	8%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Eyelids itchy sensation of		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Hypersensitivity		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Redness of eyelid conjunctiva		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Swelling		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 OAT1 725 OAT3 747 OAT2 153 OATP1B1 1079 OATP2B1 157 OCT1 620 OCT2 779	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
OATP1B1 1095	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OCT1 656	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OCT2 782	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OAT2 155	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	no
OATP2B1 162	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	no
P-gp 1932	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0022354921000708 Page: 1612.0	no
OAT1 730	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	yes
OAT3 749	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0024320501013753 Page: 2908.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:28864	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28864
ChemicalBook	CB7154445	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7154445
eMolecules	36516853	https://www.emolecules.com/cgi-bin/more?vid=36516853
eMolecules	3716283	https://www.emolecules.com/cgi-bin/more?vid=3716283
MolPort	MolPort-003-665-548	https://www.molport.com/shop/molecule-link/MolPort-003-665-548
Selleck Chemicals	Tobramycin(free-base)	http://www.selleckchem.com/products/Tobramycin(free-base).html
ZINC	ZINC000008214692	http://zinc15.docking.org/substances/ZINC000008214692

PubMed

Title	Date	PubMed
Ototoxicity of tobramycin: a clinical overview.	1976 Aug	1085788
Synthesis and anti-HIV activity of guanidinoglycosides.	2000 Dec 29	11149851
Removal of Foscarnet by hemodialysis using dialysate-side values.	2000 Mar	10795660
The effect of apramycin on colonization of pathogenic Escherichia coli in the intestinal tract of chicks.	2001 Apr	11361100
Fungal keratitis in a daily disposable soft contact lens wearer.	2001 Apr	11352448
Infectious crystalline keratopathy in an immunosuppressed patient.	2001 Apr	11352447
Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs.	2001 Apr	11310518
[Mupirocin resistant MRSA in Japan].	2001 Apr	11304996
Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis.	2001 Apr	11296179
The role of nebulized antibiotics in treating serious respiratory infections.	2001 Aug	11589477
Prevalence and analysis of risk factors for infections caused by resistant Escherichia coli strains in Anhui, China.	2001 Aug	11545486
In vitro elution of tobramycin from bioabsorbable polycaprolactone beads.	2001 Aug	11514769
[Antibiotic resistance of Staphylococcus aureus in urban experience: 6 month study in Aquitaine].	2001 Feb	11265221
Yersinia enterocolitica infection with multiple liver abscesses uncovering a primary hemochromatosis.	2001 Feb	11252417
Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998).	2001 Feb	11248523
Disseminated Pseudomonas aeruginosa and necrotizing pneumonia with complete recovery.	2001 Feb	11235039
[Effect of subinhibitory levels of aminoglycosides and fluoroquinolines on hydrophobicity and motility of Serratia marcescens].	2001 Feb	11233670
Role of bronchoalveolar lavage in immunocompromised patients with pneumonia treated with a broad spectrum antibiotic and antifungal regimen.	2001 Feb	11209099
Changes in strategies for optimal antibacterial therapy in cystic fibrosis.	2001 Feb	11165111
[Pacemaker-cable endocarditis and spondylodiscitis caused by Citrobacter koseri. Conservative treatment].	2001 Jan	11256252
[Acute pyelonephritis. Randomized multicenter double-blind study comparing ciprofloxacin with combined ciprofloxacin and tobramycin].	2001 Jan 13	11210578
Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.	2001 Jan-Feb	11478352
Perioperative microbiologic profile of the conjunctiva in photorefractive keratectomy.	2001 Jan-Feb	11201778
Recent advances in cystic fibrosis.	2001 Jul	11420207
Antibiotic therapy in intra-abdominal infections--a review on randomised clinical trials.	2001 Jul 30	11485888
Effective bactericidal activity of tobramycin and vancomycin eluted from acrylic bone cement.	2001 Jun	11480597
Changing antibiotic sensitivity patterns at a university hospital, 1992 through 1999.	2001 Jun	11440331
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.	2001 Jun	11397621
Ultraviolet recall-like phenomenon occurring after piperacillin, tobramycin, and ciprofloxacin therapy.	2001 Jun	11369921
Population kinetics of tobramycin in neonates.	2001 Jun	11360026
Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study.	2001 Jun 1	11380220
Effect of some fractions of alveolar surfactant (phospholipids and SP-A) on the bactericidal activity of different antimicrobials against some respiratory pathogens.	2001 Mar	11318808
Aminoglycoside ototoxicity.	2001 Mar	11300281
Cystic fibrosis.	2001 Mar	11182019
Management of corneal epithelial defects following laser in situ keratomileusis.	2001 Mar-Apr	11316020
In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes.	2001 Mar-Apr	11244359
[Functional characterization of a multiple-antibiotic resistant plasmid from clinical isolates of methicillin-resistant Staphylococcus aureus].	2001 May	11424487
Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II--tissue distribution.	2001 May	11394943
Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia.	2001 May	11349744
In vitro characteristics of tobramycin aerosol from ultrasonic and jet nebulizers.	2001 May	11349742
Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.	2001 May	11340683
Epidemiologic Study of Pseudomonas aeruginosa in critical patients and reservoirs.	2001 May-Jun	11395191
A comparison of cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea.	2001 Nov 1	11589975
Aminoglycoside binding to human and bacterial A-Site rRNA decoding region constructs.	2001 Oct	11557348
Gene expression in Pseudomonas aeruginosa biofilms.	2001 Oct 25	11677611
[Survey of the antibiotic sensitivity of Pseudomonas aeruginosa in France and the distribution of beta-lactam resistance mechanisms: the GERPB 1999 study].	2001 Sep	11642015
Microbiological and immunologic considerations with aerosolized drug delivery.	2001 Sep	11555566
Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.	2001 Sep	11549103
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.	2001 Sep 22	11583754
Aerosols and anti-infectious agents.	2001 Spring	11495486

Patents

Sample Use Guides

In Vivo Use Guide

KITABIS PAK is a co-packaging of tobramycin inhalation solution ampules with a PARI LC PLUS Reusable Nebulizer. Administer as follows: One single-use ampule (300 mg /5 mL) of tobramycin inhalation solution twice a day by oral inhalation in alternating periods of 28 days on drug, followed by 28 days off drug. The 300 mg/5mL dose of tobramycin inhalation solution is the same for all patients regardless of age or weight. The doses should be taken as close to 12 hours apart as possible; they should not be taken less than 6 hours apart.

Route of Administration: Respiratory

In Vitro Use Guide

High-dose tobramycin (200 ug/ml) killed 72% of Pseudomonas aeruginosa isolates

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:25:30 GMT 2025` Edited by `admin` on `Mon Mar 31 18:25:30 GMT 2025`
Record UNII	HJT0RXD7JK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NEBCIN

Preferred Name

English

TOBRAMYCIN SULFATE

Common Name

English

TOBRAMYCIN SULFATE (2:5)

Common Name

English

GERNEBCIN

Common Name

English

TOBRAMYCIN SULFATE [USP IMPURITY]

Common Name

English

STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1-6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBOHEXOPYRANOSYL-(1-4))-2-DEOXY-, D-, SULPHATE (SALT)

Common Name

English

TOBRADISTIN

Common Name

English

NEBICINA

Common Name

English

TOBRAMYCIN SULFATE [MI]

Common Name

English

TOBRAMYCIN SULPHATE

Common Name

English

D-STREPTAMINE, O-3-AMINO-3-DEOXY-ALPHA-D-GLUCOPYRANOSYL-(1.FWDARW.6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBO-HEXOPYRANOSYL- (1.FWDARW.4))-2-DEOXY-, SULPHATE (2:5) (SALT)

Common Name

English

Tobramycin sulfate [WHO-DD]

Common Name

English

TOBRAMYCIN SULFATE [ORANGE BOOK]

Common Name

English

TOBRA

Common Name

English

OBRACIN

Common Name

English

TOBRAMYCIN SULFATE [USP MONOGRAPH]

Common Name

English

TOBRAMYCIN SULFATE [MART.]

Common Name

English

STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1-6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBOHEXOPYRANOSYL-(1-4))-2-DEOXY-, D-, SULFATE (SALT)

Common Name

English

TOBRAMYCIN SULFATE [VANDF]

Common Name

English

D-STREPTAMINE, O-3-AMINO-3-DEOXY-ALPHA-D-GLUCOPYRANOSYL-(1.FWDARW.6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBO-HEXOPYRANOSYL- (1.FWDARW.4))-2-DEOXY-, SULFATE (2:5) (SALT)

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

536416